OncoMatch/Clinical Trials/NCT06699771
Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies
Is NCT06699771 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including GCC2005 and Cyclophosphamide for lymphoma, t-cell.
Treatment: GCC2005 · Cyclophosphamide · Fludarabine — This is a Phase 1 (a and b), first in human (FIH), single-arm, open-label, multicenter study to evaluate the safety, tolerability and efficacy of GCC2005 in the treatment of patients with relapsed/refractory (R/R) NK or T-cell malignancies who have received at least two prior lines of therapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD5 expression
relapsed or refractory CD5+ NK and T-cell originated malignancies
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: standard chemotherapy
relapsed or refractory disease previously treated with two or more lines of standard chemotherapies and there is no longer any treatment option considered as assessed by the Investigator
Cannot have received: CAR-T cell therapy
Participants who have had prior CAR-T or CAR-NK therapies
Cannot have received: allogenic organ transplantation
Participants with previous allogenic organ transplantation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06699771 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CAR-T cell therapy, allogenic organ transplantation disqualifies patients from enrollment.
Does this trial require CD5?
Yes, CD5 expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger and at least 19 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages